Emmessar Biotech, a company in the Commodity Chemicals industry, reported revenue of ₹0.11 crore and net profit of ₹0.14 crore for the September 2026 quarter.
Emmessar Biotech (BSE: EMMESSA) closed at ₹29.50 on 20 Nov 2026, down 4.8% over the past year. Its market capitalisation is ₹15 crore and it trades at 35.1 times earnings.
Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operating segments.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.